The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases.
 
Wei Song
No Relationships to Disclose
 
Dan Sha
No Relationships to Disclose
 
Leping Li
No Relationships to Disclose
 
Binbin Gao
No Relationships to Disclose
 
Xiaogang Sun
No Relationships to Disclose
 
Jinshen Wang
No Relationships to Disclose
 
Xu Zhou
No Relationships to Disclose
 
Liang Shang
No Relationships to Disclose
 
Changqing Jing
No Relationships to Disclose
 
Chensheng Li
No Relationships to Disclose
 
Wenmao Geng
No Relationships to Disclose
 
Xiaobo Guo
No Relationships to Disclose
 
Shulei Zhao
No Relationships to Disclose
 
Dechao Wang
No Relationships to Disclose
 
Haiyan Jing
No Relationships to Disclose
 
Cong Sun
No Relationships to Disclose
 
Zhaofei Pang
No Relationships to Disclose
 
Liguang Wang
No Relationships to Disclose
 
Ziwei Yu
No Relationships to Disclose
 
Mingyi Li
No Relationships to Disclose